Skip to content
buyModerate cluster of 4

Sireesh Appajosyula bought $50k of HEPA

Chief Operating Officer at Hepion Pharmaceuticals, Inc.. 1,250,000 shares at an average of $0.04, traded Apr 21, 2026, filed Apr 27, 2026.

Conviction score
53
Value
$50k
1,250,000 shares
Holdings after
1,250,000
change unknown
From 52-week low
+14%
low $0.04, close $0.04
From 52-week high
-90%
high $0.39, as of Apr 21, 2026

Score components

  • Role
    Director
    +15
  • Trade size
    $50k at market
    +7
  • Relative to holdings
    First purchase: no shares before this trade
    +8
  • Price context
    90% below the 52-week high
    +8
  • Cluster
    4 insiders buying within 14 days
    +15
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -1.6%, 3m +4.8%, 6m -.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

HEPAOct 9, 2026 · close 0.12
Since filing Apr 27, 2026: +93.5%SPY +9.4% · excess +84.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001493152-26-019028, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Apr 21, 2026POpen-market purchase
Common Stock, par value $0.0001 per share
+1,250,000$0.04$50k1,250,000Apr 27, 2026

Related signals

Other insiders at Hepion Pharmaceuticals, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
23Weak
HEPAbuy
Hepion Pharmaceuticals, Inc.
Danina Fisher
director
$10k
200,000 shares
-
44Moderate
HEPAbuy
Hepion Pharmaceuticals, Inc.
Sireesh Appajosyula
Chief Operating Officer
$100k
2,000,000 shares
+160%
63Notable
HEPAbuy 4
Hepion Pharmaceuticals, Inc.
Gary S. Stetz
Interim CEO
$50k
1,250,000 shares
-
64Notable
HEPAbuy 4
Hepion Pharmaceuticals, Inc.
Vincent S LoPriore
Executive Chairman
$250k
6,250,000 shares
-
53Moderate
HEPAbuy 4
Hepion Pharmaceuticals, Inc.
Michael J. Purcell
director
$50k
1,250,000 shares
-

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.